LEO Pharma aims to be dermatology market leader, acquires Bayer's dermatology unit

By Maggie Lynch contact

- Last updated on GMT

(image:Getty/Pattanaphong Khuankaew)
(image:Getty/Pattanaphong Khuankaew)

Related tags: Dermatology

LEO Pharma acquires Bayer’s prescription dermatology unit in a definitive agreement, in hopes of reaching their goal of being the leading global dermatology company by 2025.

LEO Pharma, a Denmark based company, currently, has a patient base of 80m per year. By adding brands they hope to naturally boost the number of patients they can reach each year to 125m by 2025.

A spokesperson from LEO Pharma, told us, that acquisitions are a focus to help them reach their goal by expanding the portfolio of treatments they can offer. Citing that it will help them build “critical mass”​ for LEO Pharma around the world.

The portfolio that will be acquired will include branded topical prescription treatments, as well as topical steroids. These treatments are for the treatment of acne, fungal skin infections and rosacea. LEO will not acquire Bayer’s over-the-counter dermatology portfolio.

The portfolio that will be acquired will include branded topical prescription treatments, as well as topical steroids. These treatments are for the use of acne, fungal skin infections and rosacea. LEO will not acquire Bayer’s over-the-counter dermatology portfolio.

This acquisition will integrate 450 employees from Bayer RX into LEO Pharma. LEO will also acquire global product rights and take over sales and marketing organizations in 14 countries. LEO will not have product rights in Afghanistan or Pakistan.

“The new portfolio will strengthen LEO Pharma in all regions and will thus enable us to help even more patients going forward,”​ said LEO spokesperson.

Despite moving further into dermatology, the LEO spokesperson confirmed that its focus will continue to look towards rare diseases, “Going forward, our focus will be on innovative treatments including rare diseases. The latter are a particularly interesting arena for us as there are many diseases affecting small populations, where there is no treatment today and where there is a high unmet need.”

The terms of the agreement were not disclosed.

Related news